|
Hemato-oncology
Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
Yu Ri Kim, Soo-Jeong Kim, Yong Park, Sung Yong Oh, Hwan-Jung Yun, Yeung-Chul Mun, Jin Seok Kim; the Korean Society of Hematology Lymphoma Working Party
Korean J Intern Med. 2021;36(5):1181-1189. Published online July 16, 2021
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocy..
|
|
|
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation
So Yeon Jeon, Ho-Young Yhim, Hee Sun Kim, Jeong-A Kim, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2018;33(6):1169-1181. Published online January 8, 2018
Background/Aims: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin’s lymphoma (NHL) is limited.
Methods: Consecutive patients with aggressive NHL ..
|
|
|
Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study
Young-Woo Jeon, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Woo-Sung Min, Seok-Goo Cho
Korean J Intern Med. 2015;31(5):944-952. Published online July 7, 2016
Background/Aims: Recently, large cohort studies regarding associations between autoimmune disease and lymphomas have been reported in a few Western countries. However, Asian data concerning autoimmune-related lymphomas are limited. Therefore, we evaluated the clinical characteristics and prognostic ..
|
|
|
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
Hyungwoo Cho, Dok Hyun Yoon, Jwa Hoon Kim, Young Bo Ko, Byoung Soo Kwon, In-Hye Song, Cheolwon Suh
Korean J Intern Med. 2016;31(3):605-607. Published online March 12, 2016
|
|
|
Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
Kyu-Hyoung Lim, Ho-Il Yoon, Young Ae Kang, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee
Korean J Intern Med. 2010;25(1):86-92. Published online February 26, 2010
Background/AimsThe aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymph..
|
|
|
